Engert Oliver purchased $150K of ENOV

Enovis (NYSE: ENOV) has made a binding offer to acquire eCential Robotics, a surgical robotics company. The deal is expected to close in Q4 2026, subject to regulatory approvals. eCential's Op.n® platform complements Enovis' technology portfolio, enhancing surgical precision and workflows. Both companies' CEOs expressed excitement about the strategic fit and future growth opportunities.

Enovis CORP (ENOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Enovis Announces Second Quarter 2026 Results • Second-quarter sales growth of 3% on a reported basis, 5% organic • Second-quarter Reconstructive sales growth of 8% on a reported basis, 6% organic • Reaffirmed full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and

UBS initiated coverage of four U.S. medtech firms. It assigned Buy ratings to Intuitive Surgical (ISRG) with a $500 price target and Enovis (ENOV) with a $51 target, citing growth drivers and improving fundamentals. UBS gave Inspire Medical Systems (INSP) a Sell rating with a $39 target and Integra LifeSciences (IART) a Neutral rating with a $19 target, citing competition, reimbursement and limited catalysts.

Enovis (NYSE: ENOV) shares rose about 3.6% after the company said it launched CT-RevitL, a veterinary laser therapy system, in the U.S. Enovis said the photobiomodulation device targets pain management and healing and is available immediately, with international plans later. After the move, shares traded around $26.48.

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

Enovis (ENOV) shares rose about 15% after CMS reversed previously announced reimbursement cuts affecting the company’s non-invasive bone growth stimulators, according to reports. The move followed a prior 12% drop and broader healthcare strength after a soft June jobs report. The article cites Enovis’s prior quarter results and a 2026 adjusted EPS forecast of $3.52–$3.73.